Ilmenauer Discovery Tool

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects

PRIMARY OBJECTIVES: I. To evaluate the efficacy of olaparib in two cohorts of patients with metastatic/advanced urothelial carcinoma (UC) pre-selected by deoxyribonucleic acid (DNA)-repair defects as measured by overall response rate (ORR). SECONDARY OBJECTIVES: I. To describe the effect of therapy...

Full description

Bibliographic Details
Other Involved Persons:	National Cancer Institute (NCI)
Format:	eBook
Language:	English
Published:	Bethesda (Maryland) : ClinicalTrials.gov March 15, 2019
Item Description:	Copyright: Source: ClinicalTrials.gov (no modifications made) Copyright: ClinicalTrials.gov processed this data on May 06, 2019 Copyright: Last update posted on ClinicalTrials.gov: March 15, 2019 Copyright: Last updated: 2019-05-06
Physical Description:	Online-Ressource
Subjects:	Clinical Study Clinical Trial, Phase II Carcinoma Carcinoma, Transitional Cell Clinical Study Status: Recruiting Abnormal DNA Repair ATM Gene Mutation ATR Gene Mutation BAP1 Gene Mutation BARD1 Gene Mutation BLM Gene Mutation BRCA1 Gene Mutation BRCA2 Gene Mutation BRIP1 Gene Mutation CHEK1 Gene Mutation CHEK2 Gene Mutation FANCC Gene Mutation FANCD2 Gene Mutation FANCE Gene Mutation FANCF Gene Mutation MEN1 Gene Mutation Metastatic Urothelial Carcinoma MLH1 Gene Mutation MSH2 Gene Mutation MSH6 Gene Mutation MUTYH Gene Mutation NPM1 Gene Mutation PALB2 Gene Mutation PMS2 Gene Mutation POLD1 Gene Mutation POLE Gene Mutation PRKDC Gene Mutation RAD50 Gene Mutation RAD51 Gene Mutation SMARCB1 Gene Mutation Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 Stage IV Bladder Urothelial Carcinoma AJCC v7 STK11 Gene Mutation Urothelial Carcinoma Klinische Studie Forschungsbericht
QR Code:	Show QR Code

Further Information:
https://clinicaltrials.gov/show/NCT03375307

Feedback Delivery Service Acquisition Suggestion